In vitro activity of trovafloxacin against Chlamydia pneumoniae (Q35138264)

6 August 2017

In vitro activity of trovafloxacin against Chlamydia pneumoniae (English)

1 reference

6 August 2017

Chlamydia pneumoniae

1 reference

Roblin PM

1

1 reference

6 August 2017

Kutlin A

series ordinal

2

1 reference

6 August 2017

Hammerschlag MR

series ordinal

3

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 September 1997

1 reference

Antimicrobial Agents and Chemotherapy

6 August 2017

1 reference

6 August 2017

41

1 reference

6 August 2017

9

1 reference

6 August 2017

2033-2034

1 reference

Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae

6 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=164061

Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=164061

Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=164061

Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=164061

In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=164061

Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=164061

Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=164061

A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=164061

Infection with Chlamydia pneumoniae in Brooklyn

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=164061

Persistent infection with Chlamydia pneumoniae following acute respiratory illness

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=164061

In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=164061

In vitro activities of five quinolones against Chlamydia pneumoniae

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=164061

In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens

13 July 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/9303410

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

PMCID

164061

1 reference

6 August 2017

1 reference